2025年

by 腫瘍病態学分野

2025

  1. Okada T, Natsumeda M, Fujiwara H, Higa N, Akahane T, Tsukamoto Y, Ohshima S, Horii A, Tanimoto A, Hanaya R, Shimizu H, Kakita A, Oishi M. Improved hearing in a rare, adult IDH2-mutant brainstem astrocytoma successfully treated with radiation and temozolomide. Front Oncol, 15:1555986, 2025.
  2. Yamaguchi　Y, Okada M, Otani T, On J, Shibuma S, Takino T, Watanabe J, Tsukamoto Y, Ogura R, Oishi M, Suzuki T, Ishikawa A, Sakata H, Natsumeda M. Near-infrared photoimmunotherapy in brain tumors- an unexplored frontier. Pharmaceuticals, 18(5):751, 2025.
  3. Tsukamoto Y, Natsumeda M, Shimizu H, Takahashi H, Shibuma S, Takahashi A, Shida K, Fujiwara H, Nakayama Y, Takahashi Y, Kondo R, Saito R, Eda T, Okada M, Okamoto K, Kikuchi T, Kakita A, Oishi M. Rapidly progressive scalp and lung metastases with fatal pneumothorax in glioblastoma, IDH-wildtype, with MET and CDK6 amplifications: A case report of clinical course and postmortem autopsy, including genetic analysis. Brain Tumor Pathol, 53(2):94-103, 2025. 
  4. Tsukamoto Y, Natsumeda M, Oishi M. The practice of multi-modality imaging for brain tumor resection. No Shinkei Geka, 53(2): 271-279, 2025.
  5. Watanabe T, Noto S, Natsumeda M, Kimura S, Ikarashi F, Tabata S, Takano M, Tsukamoto Y, Oishi M. Improved health-related quality of life after rehabilitation in patients with brain tumors is not affected by tumor type. Eur J Phys Rehabil Med, 61(2):239-249, 2025.
  6. Tate S, Ogawa S, Izumikawa K, Isoyama S, Mori M, Fujiwara K, Watanabe S, Ohga T, Jo U, Taniyama D, Kitajima S, Tanaka S, Onji H, Kageyama S, Yamamoto G, Saito H, Yamamori-Morita T, Okada M, Natsumeda M, Nagahama M, Kobayashi J, Ohashi A, Sasanuma H, Higashiyama S, Dan S, Pommier Y, Murai J. SLFN11-mediated ribosome biogenesis impairment induces TP53-independent apoptosis. Mol Cell, 85(5):894-912, 2025.
  7. Shibuma S, On J, Natsumeda M, Koyama A, Takahashi H, Watanabe J, Mitobe M, Nakata S, Tanaka Y, Tsukamoto Y, Okada M, Yoshimura J, Tada M, Shimizu H, Oya S, Murai J, Okamoto K, Kawashima H, Kakita A, Oishi M. Diagnosis of leptomeningeal disease in diffuse midline gliomas by detection of H3F3A K27M mutation in circulating tumor DNA of cerebrospinal fluid. Pediatr Blood Cancer, 72(4):e31535, 2025.
  8. Kanamori M, Tsuzuki S, Shibahara I, Saito K, Shimoda Y, Tanaka K, Yamaguchi S, 
  9. Takami H, Matsutani M, Suzuki T, Takabatake K, Fujimaki T, Okamoto M, Yamaguchi S, Kanamori M, Kenichiro M, Sonoda Y, Natsumeda M, Ichinose T, Nakada M, Muroi A, Ishikawa E, Takahashi M, Narita Y, Tanaka S, Higuchi F, Shin M, Mineharu Y, Arakawa Y, Kagawa N, Kawabata S, Wanibuchi M, Takayasu T, Fujii K, Ishida J, Date I, Miyake K, Fujioka Y, Kuga D, Yamashita S, Takeshima H, Shinojima N, Mukasa A, Asai A, Nishikawa R. Phase II Trial of Pathology-based Tripartite Treatment Stratification for Patients with CNS Germ Cell Tumors: A Long-term Follow-up Study, Neuro-Oncol, 27(3):828-840, 2025.
  10. Kanamori M, Shibahara I, Shimoda Y, Akiyama Y, Beppu T, Ohba S, Enomoto T, Ono T, Mitobe Y, Hanihara M, Mineharu Y, Ishida U, Asano K, Yoshida Y, Natsumeda M, Nomura S, Abe T, Yonezawa H, Katakura R, Shibui S, Kuroiwa T, Suzuki H, Takei H, Matsushita H, Saito R, Arakawa Y, Sonoda Y, Hirose Y, Kumabe T, Yamgaguchi T, Endo H, Tominaga T. Efficacy and safety of carmustine wafers, followed by radiation, temozolomide, and bevacizumab therapy, for newly diagnosed glioblastoma with maximal resection. Int J Clin Oncol, 30(1):51-61, 2025.